Industry

Repatha® now approved for adults at risk of major cardiovascular events from high LDL-C

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low Continue Reading

Lilly’s Mounjaro (tirzepatide) showed cardiovascular protection in a landmark trial

Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease Continue Reading

Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option

PRINCETON, N.J.--(BUSINESS WIRE)-- The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) – (Pfizer NYSE: PFE) Alliance today announced a new direct-to-patient option for purchasing Eliquis® (apixaban) via our Alliance’s patient resource Eliquis 360 Support. The offering provides an... Continue Reading

Heartflow Plaque Analysis Awarded First Coverage Recommendation by Radiology Benefits Manager

MOUNTAIN VIEW, Calif. — July 11, 2025 — Heartflow, Inc., the leader in AI technology for coronary artery disease (CAD), today announced Heartflow Plaque Analysis will be included in updated cardiac imaging guidelines by radiology benefit manager EviCore, which provides coverage... Continue Reading

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high CV risk

INDIANAPOLIS, June 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, today announced a definitive agreement for Lilly to acquire Verve. Read more... Continue Reading

Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials

INDIANAPOLIS, June 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in single-dose vials for $499 per month through LillyDirect's Self Pay Pharmacy Solutions and... Continue Reading

ALYKA Health now a Supporting Partner of the American Society for Preventive Cardiology

ATLANTA, GA, UNITED STATES, June 16, 2025 /EINPresswire.com/ -- ALYKA Health, a digital health company that partners with providers to empower patients to improve their cardiovascular health and outcomes, announced that it is now a supporting partner of the American Society for Preventive... Continue Reading

Regeneron Expands Clinical-Stage Obesity Portfolio

TARRYTOWN, N.Y., June 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited (“Hansoh”) to acquire exclusive clinical development and commercial rights outside of... Continue Reading

Interim Results from Ongoing Phase 2 COURAGE Trial

TARRYTOWN, N.Y., June 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced interim results from the ongoing Phase 2 COURAGE trial investigating novel combinations of semaglutide (GLP-1 receptor agonist) and trevogrumab (anti-GDF8/anti-myostatin) with or... Continue Reading

Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results

INDIANAPOLIS, April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and... Continue Reading

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type TTR

PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients with variant and... Continue Reading

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study

THE WOODLANDS, Texas, March 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced topline results from the PROGRESS Phase 2b study evaluating pilavapadin (LX9211), an oral, non-opioid investigational adaptor-associated kinase 1 (AAK1) inhibitor in adult... Continue Reading